U.S. markets closed

Vaxcyte, Inc. (PCVX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.91-0.59 (-1.30%)
At close: 04:00PM EST
45.99 +1.08 (+2.40%)
After hours: 07:37PM EST

Vaxcyte, Inc.

825 Industrial Road
Suite 300
San Carlos, CA 94070
United States
650 837 0111

Full Time Employees89

Key Executives

NameTitlePayExercisedYear Born
Mr. Grant E. Pickering M.B.A.Co-Founder, CEO & Director938.36k5.12M1968
Mr. Andrew L. Guggenhime M.B.A.Pres & CFO716.87k150.42k1968
Mr. James Wassil M.B.A., M.S.Exec. VP & COO659.63k156.8k1969
Mr. Paul W. Sauer M.B.A., MBASr. VP of Process Devel. & Manufacturing525.94k194.66k1961
Mr. Harp Dhaliwal M.B.A.Sr. VP of Commercial Manufacturing & Supply Chain146.48kN/A1973
Dr. Ashish Khanna M.B.A., Ph.D.Co-Founder and Chief Bus. OfficerN/AN/A1972
Dr. Jeff Fairman Ph.D.Co-Founder & VP of ResearchN/AN/A1964
Ms. Janet GraesserVP of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Mikhail Eydelman J.D.Sr. VP, Gen. Counsel & Corp. Sec.N/AN/A1978
Karen AldereteExec. Director of HRN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Corporate Governance

Vaxcyte, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.